Therapeutic Area | MeSH |
---|---|
nutritional and metabolic diseases | D009750 |
endocrine system diseases | D004700 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
AVANDARYL | SB Pharmco | N-021700 DISCN | 2005-11-23 | 5 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
duetact | New Drug Application | 2022-10-24 |
glimepiride | ANDA | 2025-03-25 |
glimepiride 3 mg | ANDA | 2024-08-20 |
pioglitazone and glimepiride | NDA authorized generic | 2021-12-16 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | — | — | 1 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 1 | — | — | 1 |
Drug common name | Glimepiride |
INN | glimepiride |
Description | Glimepiride is a sulfonamide, a N-acylurea and a N-sulfonylurea. It has a role as a hypoglycemic agent and an insulin secretagogue. |
Classification | Small molecule |
Drug class | antidiabetics |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O |
PDB | — |
CAS-ID | 93479-97-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1481 |
ChEBI ID | 5383 |
PubChem CID | 3476 |
DrugBank | DB00222 |
UNII ID | 6KY687524K (ChemIDplus, GSRS) |